668 related articles for article (PubMed ID: 27216487)
1. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
2. Abuse liability profile of three substituted tryptamines.
Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
[TBL] [Abstract][Full Text] [Related]
3. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
[TBL] [Abstract][Full Text] [Related]
4. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV; Gopalakrishnan A; Anderson LL; Feih JT; Shulgin AT; Daley PF; Ruoho AE
J Neural Transm (Vienna); 2009 Dec; 116(12):1591-9. PubMed ID: 19756361
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
[TBL] [Abstract][Full Text] [Related]
6. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
[TBL] [Abstract][Full Text] [Related]
7. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
Blair JB; Marona-Lewicka D; Kanthasamy A; Lucaites VL; Nelson DL; Nichols DE
J Med Chem; 1999 Mar; 42(6):1106-11. PubMed ID: 10090793
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
Nelson DL; Lucaites VL; Wainscott DB; Glennon RA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):1-6. PubMed ID: 9933142
[TBL] [Abstract][Full Text] [Related]
9. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
[TBL] [Abstract][Full Text] [Related]
10. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
11. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
Fantegrossi WE; Harrington AW; Kiessel CL; Eckler JR; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
Pharmacol Biochem Behav; 2006 Jan; 83(1):122-9. PubMed ID: 16460788
[TBL] [Abstract][Full Text] [Related]
12. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
13. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).
Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Hoang K; Wallach J; Halberstadt AL
Drug Test Anal; 2016 Sep; 8(9):891-902. PubMed ID: 26456305
[TBL] [Abstract][Full Text] [Related]
14. Psychedelics and the human receptorome.
Ray TS
PLoS One; 2010 Feb; 5(2):e9019. PubMed ID: 20126400
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
Newton RA; Phipps SL; Flanigan TP; Newberry NR; Carey JE; Kumar C; McDonald B; Chen C; Elliott JM
J Neurochem; 1996 Dec; 67(6):2521-31. PubMed ID: 8931486
[TBL] [Abstract][Full Text] [Related]
16. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
Kim SK; Li Y; Abrol R; Heo J; Goddard WA
J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232
[TBL] [Abstract][Full Text] [Related]
17. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of novel psychoactive benzofurans.
Rickli A; Kopf S; Hoener MC; Liechti ME
Br J Pharmacol; 2015 Jul; 172(13):3412-25. PubMed ID: 25765500
[TBL] [Abstract][Full Text] [Related]
19. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.
Winter JC
Psychopharmacology (Berl); 2009 Apr; 203(2):251-63. PubMed ID: 18979087
[TBL] [Abstract][Full Text] [Related]
20. Discriminative stimulus effects of N,N-diisopropyltryptamine.
Carbonaro TM; Forster MJ; Gatch MB
Psychopharmacology (Berl); 2013 Mar; 226(2):241-6. PubMed ID: 23070023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
